Zacks Research Has Optimistic Outlook of Integer Q3 Earnings

Key Points

• Zacks Research has raised its Q3 2025 earnings estimate for Integer Holdings Corporation to $1.68 per share, which is an increase from the previous estimate of $1.67.
• Integer reported earnings of $1.55 per share last quarter, which fell short of the consensus estimate of $1.57, although its revenue of $476 million surpassed expectations.
• Despite recent price target reductions from various analysts, Integer holds a Moderate Buy rating overall with a consensus price target of $140.25.

Integer Holdings Corporation (NYSE:ITGR - Free Report) - Research analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for shares of Integer in a report issued on Thursday, August 14th. Zacks Research analyst Team now forecasts that the medical equipment provider will earn $1.68 per share for the quarter, up from their previous estimate of $1.67. The consensus estimate for Integer's current full-year earnings is $6.01 per share. Zacks Research also issued estimates for Integer's Q4 2025 earnings at $1.83 EPS, FY2025 earnings at $6.37 EPS, Q1 2026 earnings at $1.58 EPS, Q2 2026 earnings at $1.75 EPS, Q3 2026 earnings at $1.85 EPS, Q4 2026 earnings at $1.93 EPS, FY2026 earnings at $7.10 EPS, Q1 2027 earnings at $1.77 EPS, Q2 2027 earnings at $1.94 EPS and FY2027 earnings at $7.73 EPS.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The business had revenue of $476.00 million during the quarter, compared to analyst estimates of $464.37 million. During the same period in the prior year, the business posted $1.30 EPS. Integer's revenue was up 11.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.250-6.510 EPS.

ITGR has been the subject of a number of other research reports. Wall Street Zen raised shares of Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th. Citigroup raised Integer from a "hold" rating to a "strong-buy" rating and upped their target price for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Wells Fargo & Company lowered their price target on Integer from $152.00 to $132.00 and set an "overweight" rating for the company in a research report on Friday, July 25th. Benchmark dropped their price target on Integer from $150.00 to $140.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Finally, Truist Financial reduced their price objective on Integer from $145.00 to $137.00 and set a "buy" rating for the company in a research note on Friday, July 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Integer presently has an average rating of "Buy" and an average target price of $140.25.

Integer Stock Performance

Shares of Integer stock traded up $3.8190 during midday trading on Monday, hitting $110.6490. The company had a trading volume of 256,433 shares, compared to its average volume of 373,536. The company has a fifty day simple moving average of $113.76 and a 200 day simple moving average of $119.20. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of 48.74, a PEG ratio of 0.84 and a beta of 1.02. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72. Integer has a 12-month low of $104.93 and a 12-month high of $146.36.

Insider Activity at Integer

In other Integer news, Director Donald J. Spence sold 14,739 shares of Integer stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total value of $1,774,280.82. Following the completion of the transaction, the director owned 18,781 shares of the company's stock, valued at approximately $2,260,856.78. The trade was a 43.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Martin C. Maxwell sold 8,720 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $120.56, for a total transaction of $1,051,283.20. Following the completion of the transaction, the director owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. This trade represents a 28.23% decrease in their position. The disclosure for this sale can be found here. 2.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Integer

A number of large investors have recently bought and sold shares of ITGR. State of Wyoming acquired a new position in Integer in the 2nd quarter worth about $233,000. Public Sector Pension Investment Board increased its position in shares of Integer by 11.8% in the second quarter. Public Sector Pension Investment Board now owns 118,933 shares of the medical equipment provider's stock valued at $14,625,000 after buying an additional 12,551 shares in the last quarter. FORA Capital LLC purchased a new stake in shares of Integer in the second quarter valued at approximately $535,000. Tower Research Capital LLC TRC raised its stake in shares of Integer by 74.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,832 shares of the medical equipment provider's stock worth $471,000 after buying an additional 1,639 shares during the period. Finally, State of Tennessee Department of Treasury raised its stake in shares of Integer by 54.1% during the 2nd quarter. State of Tennessee Department of Treasury now owns 15,369 shares of the medical equipment provider's stock worth $1,890,000 after buying an additional 5,397 shares during the period. Institutional investors and hedge funds own 99.29% of the company's stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.